Gastroenterology & GI Surgery | Featured Specialties | UC Davis Health

An international clinical trial involving UC Davis Health suggests the investigational drug Elafibranor is a potential novel treatment for patients with primary biliary cholangitis. Results showed significant improvements in biomarkers of disease progression. The results of the clinical trial were published in The New England Journal of Medicine. They were also presented by Christopher Bowlus, M.D., chief of Gastroenterology and Hepatology at UC Davis Health at The Liver Meeting, hosted by the American Association for the Study of Liver Disease.

Interventional gastroenterologists at UC Davis Health are offering new endoscopic procedures in the new leading-edge outpatient endoscopy suite. Some of the procedures provided include endoscopic treatment for Achalasia, characterization of pancreatic cysts using real time laser microscopy, and removal of early-stage tumors, among many others. The procedures are visually aided with advanced integrated fluoroscopy suites, 3-D mobile C-arm system, and more.

UC Davis Health researchers have infused their first Wilson Disease patient with gene therapy as part of a groundbreaking new clinical trial. The treatment has the potential to address the underlying cause of the disease. The industry-funded clinical trial with Ultragenyx is evaluating UX701, an investigational adeno-associated virus (AAV) vector-based gene therapy. UC Davis Health is one of just seven health care institutions worldwide to infuse a patient with this new gene therapy.